BD names interim CFO as DelOrefice departs in December

BD (NYSE: BDX) announced that Chief Financial Officer Chris DelOrefice will leave the company on Dec. 5, 2025, to pursue a new professional opportunity. The medical technology company has named Vitor Roque, senior vice president of finance, business units and corporate financial planning and analysis, as interim CFO effective upon DelOrefice's departure.

DelOrefice served as executive vice president and CFO for four years. Roque has worked at BD for two decades in various finance leadership roles across regions, business units and segments, including supporting key acquisitions.

The company provided preliminary unaudited revenue results for the fourth quarter and full year fiscal 2025, which ended Sept. 30, 2025. Fourth quarter revenue reached approximately $5.9 billion, representing an estimated increase of 8.3% on a reported basis, 7.0% on a currency-neutral basis and 3.9% on an organic basis.

Full year preliminary revenue totaled approximately $21.8 billion, marking an estimated increase of 8.2% on a reported basis, 7.7% on an adjusted currency-neutral basis and 2.9% on an organic basis compared to the prior year.

"While we continue to navigate a dynamic macro environment that had a greater than anticipated impact this quarter in areas we have been closely monitoring, specifically Pharmaceutical Systems vaccines and Biosciences academic and government research, we delivered strong growth across multiple areas including the BD Interventional segment, Advanced Patient Monitoring and Medication Delivery Solutions," said Tom Polen, chairman, CEO and president of BD.

BD expects to deliver full year fiscal 2025 adjusted diluted earnings per share at or above the midpoint of its previously issued guidance. The company will host an earnings call at 8 a.m. ET on Nov. 6, 2025, to discuss its fourth quarter and full year fiscal 2025 financial results.

You May Also Be Interested In

• Agilent completes acquisition of Biocare Medical
• NorthStar and Viking file F-4 for $300M SPAC merger
• Glaukos completes enrollment in Phase 2 eye disease drug study